RESEARCH ARTICLE

ALENDRONATE SODIUM IN OSTEOARTHRITIS: EFFECTS ON ANABOLIC, CARTILAGE DEGRADATIVE MARKERS AND THE CLINICAL ACTIVITY.

Sinaa Abdul Amir Kadhim1, Haidar Mahdi Jawad2 and Sami Salman Shihab3.

1. Ass. Prof. in Pharmacology Department. College of Medicine, University of Al-Qadisiyah.Iraq.
2. Ass. Prof in Pharmacology Department. College of Medicine, University of Baghdad.Iraq.
3. Professor. College of Medicine, University of Baghdad.Iraq.

Objective: Osteoarthritis (OA) is a common arthritic disorder and responsible for 2% of disability in all world. OA affects all joint parts including cartilage, bone and synovium which characterized by degradation of cartilage, subchondral bone turn over and osteophytes formation.

Aim of the study: To evaluate the effect of alendronate sodium (ALN) on disease activity and physical function, evaluate the biochemical parameters that are related to OA patients and study the impact of ALN on bone anabolic and degradative marker, and to determine its effectiveness in slowing progression of disease.

Patients and methods: 116 OA patients over 45 years old with Kellgren and Lawrence X-ray grade II and more were enrolled in this study. Base line assessment was done, Kellgren and Lawrence X-ray grading, WOMAC scoring, body mass index and the biochemical parameters with enzyme-linked immunosorbent assay (ELISA) analysis of serum TGF (transforming growth factor) beta 1 and C-terminal cross linked -telopeptide of type II collagen (CTXII). They were instructed to take ALN 10 mg daily. Reassessment was done after 3 months.

Results: A significant symptomatic improvement in WOMAC scoring regarding pain and stiffness were observed associated with significant reduction in serum CTXII, TGF beta 1. A no significant reduction in serum calcium with no significant changes in serum Alkaline phosphatase C-reactive protein function and joint space width were also reported.

Conclusion: ALN in patients with OA has clinical efficacy in reducing symptoms especially pain probably through inhibition of TGF beta 1 with no significant structural improvement despite reduction of CTXII, and may help delay and prevent further disease progression probably through inhibition of TGF β1 activity in the subchondral bone.
**Introduction:**

Osteoarthritis (OA) is a slowly progressive degeneration of articular cartilage with subsequently joint space width (JSW) reduction (Blagojevic et al., 2010), a common form of arthritic problem (Abramson et al., 2006). In spite the fact that OA has been believed to be principally a cartilage defect associated with focal articular cartilage degradation (Felson, 2006). It has been found that a solid and stable aspects of subchondral bone is needed for articular cartilage in load-bearing articular joints, which affects the activity of subchondral bone in OA (Majjoub et al., 2012; Suri and Walsh, 2012). The structural changes throughout OA progression including decreased mineralization of the trabecular structure, amplified turnover in the subchondral bone, defects in bone marrow and subchondral plate sclerosis (Karsdal et al., 2014). OA is characterized by a repetitive inflammatory aspect of the articular cartilage due to focal defect or erosion of the cartilage and hypertrophic changes of osteoblastic function or osteophytosis (Esser and Bailey, 2011). These defining abnormalities result in a reduction in JSW leading to painful, immobile, and disabling joint (Ringdahl and Pandit, 2011). Meanwhile, when bone resorption is decreased a range of biochemical investigations has demonstrated positive events on cartilage health (Radin and Rose, 1986). OA is a multifactorial disorders (Berenbaum, 2013). Risk factor for OA like age, OA is highly age-related because old cartilage expresses changes in TGF (transforming growth factor) -β signaling with decrease protection capacity (Vander, 2014). Other factors like gender (Patricia et al., 2011), race (Cruz-Almeida et al., 2014), overestress (Voelker, 2011) and sex hormone (Jorge et al., 2009). OA can be classified as primary (idiopathic) if its cause is not well defined and secondary when there is a certain events causing OA (Brandt et al., 1986).

Cytokines such as TNF-alpha and IL-1 increase matrix metalloproteinases (MMP) gene expression and block chondrocyte balancing pathway (Scanzello and Goldring, 2012). IL-4, IL-10, and IL-13 have the ability to reduce synthesis of both TNF-alpha and IL-1beta, and to control MMP activity (Fernandes et al., 2002). IL-1 further affect the action of certain growth factors, such as transforming growth factor-beta (TGF-β) (Alejandro, 2011). TGF-β1 responsible for maintaining homeostasis between articular cartilage and subchondral bone (Gehua and Xu, 2014). TGF-β1 is found in high level in subchondral bone from humans with OA (Gehua et al., 2013). High concentrations of TGF-β1 enhance formation of nestin-positive mesenchymal stem cell clusters, which enhances the generation of marrow osteoid islets associated with high levels of angiogenesis (Gehua et al., 2013). It has been found that spinal osteofly formation is associated with alternation in the TGF-β1 gene in Japanese women (Yamada, 2000; Yamada et al., 2000) and targeting TGF β1 could be a therapeutic approach to managing OA patients (Gehua et al., 2013).

Findings in OA joints include increase size of bone tissue, crepitus, effusions, and decreased range of motion. Tenderness on palpation and pain on passive movement are also common, even though not exclusive to OA (Joseph et al., 2009). Primary OA is typically diagnosed according to clinical and radiographic imaging findings (Hunter, 2008). Kellgren and Lawrence (K-L) system is the most often used (Kellgren and Lawrence, 1957). It has been discovered that a combination of both pharmacological and non-pharmacological therapies exert a beneficial role in managing patients with knee osteoarthritis (Alshami, 2014).

Alendronate sodium (ALN) is a nonhormonal therapeutic agent, synthetic analogs of pyrophosphate attach to the hydroxyapatite, one of bone contents. It considered as a member of bisphosphonates. ALN is a 4-amino-1-hydroxy-1-phosphonobutyl, hydroxyphosphinate, bisphosphonic acid monosodium salt trihydrate. ALN is a potent antiresorptive agent poorly absorbed from the gastrointestinal tract, eliminated by active secretion of drug by renal transport system, with very long half-life (1 to 10 years) of bisphosphonates in bone, which related to different levels of bone turnover among species (Lin, 1996). The bisphosphonate inhibitory action on bone resorption is resulted from accumulation of bisphosphonate in osteoclasts after released from bone surfaces during bone resorption. Bisphosphonates inhibit farnesy pyrophosphate synthase. This prevents the synthesis of isoprenoid lipids by disruption normal function. Isopentenyl diphosphate metabolite trapped. Thus, bisphosphonate disrupt osteoclast function leading to reduction of bone resorption (Michael et al., 2011; Frank et al., 2011). Bisphosphonates, including ALN were reversing the pathophysiological features, leading to decrease bone turnover and significant increment in mineral density of bone, of postmenopausal osteoporosis (Richard et al., 2011). Animal model of study, it has been demonstrated that ALN protects chondrocyte from OA events induced by IL-1beta by increasing Collagen II and reduction of MMP-13 within chondrocytes (Wang et al., 2011).

ALN is used in osteoporotic postmenopausal lady (Nijs et al., 2006; Rogers, 2003), corticosteroid-associated osteoporosis (Nijset et al., 2006), pague's disease (Reid and Hosking., 2011) and osteogenesis imperfecta (Evans et al.,
In spite of the high benefit of ALN, it induces gastric mucosal damages (İşeri et al., 2005), esophageal problem (Naniwa et al., 2008). Osteonecrosis of the jaw (Khosla et al., 2007).

The certain contraindications to ALN are acute inflammations of the gastrointestinal tract (Cryer and Bauer, 2002), hypersensitivity (Naniwa et al., 2008), abnormalities of the esophagus (Naniwa et al., 2008), inability to stand or sit upright for at least 30 minutes (Zentiva, 2016), hypocalcaemia (Zentiva, 2016), renal impairment (Miguel et al., 2013) and osteomalacia (Lenart et al., 2008).

A potential benefit of antiresorptive agents, bisphosphonates, results from experimental studies have shown promising results in treatment of OA (Tim, 2003). ALN intake, in symptomatic hip OA, is effective in pain reduction associated with no significant observation obtained in OA pathology after 2 years treatment(Nishii et al., 2013). ALN was associated with less spinal osteophyte and joint space narrowing progression (Neogi et al., 2008; Siebelt et al., 2014).

Animal model of study has suggested that Local elution of ALN acid leads to a dose-dependent increment of bone formation (Bobyn et al., 2014) and the subcutaneous ALN injections for rabbits OA resulted in reduction of cartilage degeneration, stopping of bone loss with observed improvement in subchondral bone microarchitecture (Mohan et al., 2013). Both in vitro and in vivo studies have found that ALN has the ability to protect chondrocytes by decreasing MMP-13 expression (Hu et al., 2009). ALN has the ability to reduce remodeling of subchondral bone leading to important protective effect on articular cartilage (He et al., 2012; Mohan et al., 2013). TGF beta can be defensive as well as harmful for articular cartilage in OA. High levels of active TGF-β1 in subchondral bone leads to initiation of the pathological events of OA (Geheuet al., 2013) and a potential role of TGF beta signaling in OA development were observed, with significant correlation between activin receptor-like kinase 1 (ALK1) receptor, (receptor for action of TGF beta) and MMP-13 expression (van der et al., 2010). In rat with anterior cruciate ligament transection model, bone resorption markedly elevated, ALN inhibit Subchondral bone remodeling, which play a role in the OA pathogenesis, suggesting that ALN or other bone resorption inhibitors could potentially express DMOAD (Hayami et al., 2004). Old cartilage finds to be less protected by TGF-β and express significant changes in TGF-β signaling pathways. during aging. Loss of the protective Smad2/3 pathway can give an explanation for the relationship between aging and OA (Van der, 2014). High-dose ALN leads to complete blockage in the local elevation in MMP-13 and TGF β, which could decrease TGF β enhancement by blocking MMP-13 expression in chondrocytes, important in the pathogenesis of OA, so ALN or other bone resorption inhibitors could potentially be used in OA treatment DMOAD (Tadashi et al., 2004). ALN treatment and physical activity exercised increased cartilage content and reduce OA progression (Siebelt et al., 2014).

**Patients and methods:-**

116 OA patients over 45 years old with Kellgren and Lawrence X-ray grade 2 and more will enrolled in this study. The male patients were 32 while the female were 84 giving the male to female ratio of 1:2.63. The patients were habitants of the city of Al-Diwayhia and Baghdad cities and had the Iraq nationality. Laboratory equipment and reagents were of the highest available grades. Base line assessment were done in form of Kellgren and Lawrence X-ray grading (Kellgren and Lawrence, 1957), WOMAC scoring (Falk et al., 2008), body mass index and the biochemical parameters (serum calcium (Ca), alkaline phosphate (ALK), CTXII (ELISA) and TGF beta 1 (ELISA kit)). OA patients were instructed to take 10 mg alendronate sodium tablet orally at the morning, reassessment was done after 3 months. Statistical analysis: Data were expressed as mean standard deviation. Comparison was done using pared t-test.

**Results:-**

Demographic characteristic of the study population:The total number of cases enrolled in the present study was 116, 32 male and 84 female with a male to female ratio of 1:2.63. Mean age of patients was 54.68±5.16 years and the age range was 45-65 years, whereas the mean body mass index (BMI) was 30.21±5.91 and it ranged from 21.87 to 37.81 kg/m².

There was no significant change in mean Alkaline phosphatase before and after treatment, with no significant reduction in mean serum calcium and CRP as shown in table (1) and figures (1 and 2) through (3).
Table 1: Biochemical and serological parameters: Comparison of mean serum Alkaline phosphatase, calcium and CRP before and after 3 months treatment with ALN.

| Parameter       | Before (mg/dl) | After (mg/dl) | P-value |
|-----------------|----------------|---------------|---------|
|                 | Mean           | SD            | Mean    | SD     |          |
| Alkaline phosphatase | 105.64         | 25.69         | 108.08  | 24.05  | 0.055    |
| Serum calcium   | 9.79           | 0.74          | 9.67    | 1.30   | 0.245    |
| CRP             | 9.05           | 7.93          | 8.28    | 8.21   | 0.221    |

![Figure 1](image1.png)

**Figure 1:** Mean serum Alkaline phosphatase level before and after 3 months treatment with 10 mg ALN.

![Figure 2](image2.png)

**Figure 2:** Mean serum calcium level before and after 3 months treatment with 10 mg ALN.
**Figure (3):** Mean CRP level before and after 3 months treatment with 10 mg ALN.

**Figure 4:** Mean CTXII level before and after 3 months treatment with 10 mg ALN.

**Table 3:** Changes in mean markers: CTXII and TGF-β levels before and after 3 months treatment with 10 mg ALN.

| Parameter | Before | SD  | After | SD  | P-value |
|-----------|--------|-----|-------|-----|---------|
| CTXII     | 6.93   | 3.83| 4.35  | 2.66| <0.001  |
| TGF-β1    | 257.10 | 219.87| 175.12| 118.83| <0.001|

*Significant difference*
Figure 5: Mean TGF-β1 level before and after 3 months treatment with 10 mg ALN.

Table 4: Clinical parameters including Changes in mean JSW and WOMAC domains before and after 3 months treatment with 10 mg ALN.

| Parameter   | Before | After |
|-------------|--------|-------|
| JSW (mm)    | 2.76   | 2.80  |
| Pain        | 7.93   | 5.41  |
| Function    | 40.39  | 39.54 |

P-values:
- JSW (mm): 0.295
- Pain: <0.001
- Function: 0.661

Figure 6: Mean JSW before and after 3 months treatment with 10 mg ALN.
Figure 7: Mean pain score level before and after 3 months treatment with 10 mg ALN.

* significant

Figure 8: Mean function score level before and after 3 months treatment with ALN.

Discussion:
The mainstay of pharmacological therapy of OA is reducing pain and cartilage protection. Significant improvement in Western Ontario and McMaster Universities (WOMAC) scores together with no significant alteration in Kellgren-Lawrence grade (KL) joint space width (JSW) were stated by the current study. The present study showed that ALN use was associated with reduced knee pain severity as assessed by WOMAC scores. In agreement with our finding, Carbone and coworkers in 2004 reported significant reduction in pain according to WOMAC score in patients with OA after 3 years treatment with ALN. In agreement with current results, placebo control trail has found that there was a substantial improvement in total WOMAC score after ALN treatment and best improvement happened at week 4 (Jokar et al., 2010). Nishii and coworkers in 2013 suggested that 2 years ALN intake is effective in pain suppression associated with no significant alteration obtained in OA changes (radiological JSW). Same advantages for bisphosphonate obtained in reducing pain symptoms were reported with clodronate (Rossiniet al., 2015) and risedronate (Spector et al., 2005). Clifton and coworkers in 2006 demonstrated that there was no significant changes in WOMAC between the placebo and risedronate treated groups.
The current study demonstrated that changes in mean serum calcium, three months after treatment with ALN, were not significant despite minor reduction in calcium level. The early prevention of resorption of bone produces a decrease in serum calcium which resulted to raised parathyroid hormone (PTH), and eventually a rise in 1,25-dihydroxyvitamin D. The bisphosphonate induced secondary hyperparathyroidism also resulted in conservation of urinary calcium and phosphaturia, and a decrease in serum phosphate. The rise in the PTH after bisphosphonate treatment is a response to the variation in serum calcium and may happen even in the presence of hypercalcæmia, and this can lead to confusion in the explanation of PTH results (Vasikaran et al., 2001). This finding is go with the results were obtained by Heckbert and coworkers in 2008, Poole and coworkers in 2007, Reid and coworkers in 2002 and Vasikaran and coworkers in 2001.

Regarding C-reactive protein (CRP), the current study showed an insignificant reduction in its level. It has been found that the two main acute-phase proteins reaction are C-reactive protein (CRP) and serum amyloid A, both of which can rise up to 1000 times over normal range following an acute phase reaction (APR) (Ceciliani et al., 2002). The pathogenesis of APR has been disclosed only recently. It has been hypothesized that intravenous bisphosphonate are taken up by endocytic cells, possibly monocytes or dendritic cells, resulting in the inhibition of farnesyl pyrophosphate (FPP) synthase. This inhibition results in a lack of geranylation and farnesylation of translated little guanosine triphosphate (GTP). GTPase participate with several essential cellular actions for survival. Moreover, the FPP synthase stoppage causes intracellular accumulation of isoprenyl pyrophosphate metabolites upstream of FPP synthase in the pathway of the mevalonate (Roelofs et al., 2006). Especially, this results in the aggregation of dimethylallyl pyrophosphate and isopentenyl pyrophosphate (IPP), that are powerful assists of the gama delta T-cell receptor (Galluzzo et al., 2007). They are naturally detected by gama delta T cells with eventual activation and liberation of TNF (tumor necrotizing factor)-beta, IFN (interferon) - gama and IL (interleukin) - 6, that are the proinflammatory cytokines enrolled in the initiation and maintenance of APR (Galluzzo et al., 2007). The current CRP result is in accordance with finding of Evio in 2006 who found no significant alteration in its CRP level in ALN treated osteoporotic patients and Bertoldo and coworkers in 2010 who stated that CRP shows significant rise within 2 days after intravenous infusion of bisphosphonate then it returns to normal levels.

No significant change in mean alkaline phosphatase (ALP) before and after treatment with ALN was reported in current study. Measurement of serum bone specific ALP may be used for monitoring bone anti-resorption treatment as the reduction in bone turnover is reflected in the form of reduced serum bone specific ALP (Kress, 1998); This may be explained by the fact that measuring serum total ALP may not reflect minor changes in bone specific ALP and also that patients in the current study had no significant osteoporosis. Failure of ALN in reducing bone resorption cannot be accepted as an explanation for the lack of the change of serum ALP because bone density has been shown to increase in studies carried out by Horikawa and coworkers in 2015 and Waikakul and coworkers in 2011. The current finding in agreement with Waikakul and coworkers in 2011, who studied the effect of ALN in patients with osteoporosis for 12 months; Horikawa and coworkers in 2015, who studied the effect of intravenous and oral treatment with ALN in patients with osteoporosis for one year. However, these results are in contradiction to the results obtained by Kress in 1998, who found that, in osteoporosis, there was highly significant reduction in bone specific alkaline phosphatase after three months ALN treatment. However serum total ALP did not show significant reduction neither in the present study nor in the studies carried out by Horikawa and coworkers in 2015 and Waikakul and coworkers in 2011. This is a good indicator that treatment with ALN did not affect liver metabolism.

Significant reduction in serum transforming growth factor beta 1(TGF-β1) levels following ALN treatment was made in the current study. It has been shown, in an experimental study, that TGF–β1 is activated in the subchondral bone as a response to changed mechanical force in an anterior cruciate ligament transection (ACL) in mouse model with OA (Zhen et al., 2013). High levels of TGF–β1 caused the existence of nestin positive mesenchymal stem cell (MSC) clusters causing aberrant bone formation associated with increased neovascularization. Stoppage of TGF–β activity in subchondral bone reduced degeneration of OA joint cartilage (Zhen et al., 2013). It is worth to mention, deactivation of the TGF–β type II receptor (TβRII) in nestin-positive MSCs minimized process of OA in ACLT mice (Zhen et al., 2013). Thus, high levels of functioning TGF–β1 in the subchondral bone started the pathological events of OA, blockage of which may be a possible therapeutic approach (Zhen et al., 2013; Livshits et al., 2010). An experimental study has reported that induction of high level of TGF-β1 in bone morrow of mouse leading to abnormal bone remodeling, defects in the subchondral bone, including abnormality in bone mineral density and microstructure (Jiao et al., 2014). However, increase TGF-β1 associated with abnormal reshaping of subchondral
bone which increase the possibility of progressive degradation of mandibular condylar cartilage and OA progression (Jiao et al., 2014). Aberrant functioning of TGF-β in the subchondral osseous tissue in response to an aberrant mechanical load induces development of osteoid islets at the starting of OA. Subsequently, modulation of subchondral bone structure varies the distribution of stress on the joint cartilage and causes its degeneration. Thus, stoppage of TGF-β activity in the subchondral osseous tissue may give a new approach for treatment of OA (Zhenet et al., 2014). Others, response to aberrant mechanical load, TGF-βs were liberated, stimulated and aggregated in subchondral bone to activate abnormal bone synthesis and neovascularization through recruitment of nestin-positive MSCs or osteoprogenitor cells throughout the pathological events of OA; prevention of this process may be a possible therapeutic avenue to treat OA (Jie et al., 2014). In contrary to our results, it has been shown that ALN treatment increased serum TGF-β1 levels in experimental rat one year after treatment (Jia et al., 2013); however, other published articles showed that administration of ALN has markedly reduced TGF-β1 expression. So it is well obvious that reduction of TGF-β1 by ALN, as shown in the present study, is of great help in ameliorating OA.

The current study showed significant reduction in serum CTXII, a cartilage degenerative marker. In agreement with Nishii and coworkers in 2013, the importance of reduction in CTX-II on suppression of cartilage degeneration confirmed by other studies (Willemet et al., 2013; Damet et al., 2009) so the reduction in level of CTX-II in the present study may be considered as one of the mode of ALN action in OA.

Conclusions:
The use of Alendronate in patients with osteoarthritis has clinical efficacy in reducing symptoms especially pain probably through inhibition of TGF beta 1 with no structural improvement and may help delay and prevent further disease progression probably through inhibition of TGF β1 activity in the subchondral bone. The reduction in level of CTX-II in the present study may be considered as one of the mode of actions of alendronate in patients with OA.

References:
1. Alejandro M. IL1 and its role in osteoarthritis. OpenJournal of medicine. Vol 1, No 1 (2011).
2. Alshami A. Knee osteoarthritis related pain: a narrative review of diagnosis and treatment. Int J Health Sci (Qassim). 2014 Jan; 8(1): 85–104.
3. Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage. 2013, 21: 16-21.
4. Bertoldo F., Pancheri S., Zenari S., et al. Serum 25-Hydroxyvitamin D Levels Modulate the Acute-Phase Response Associated With the First Nitrogen-Containing Bisphosphonate Infusion. Journal of Bone and Mineral Research 2010; 25 (3): 447–454.
5. Blagojevic M, Jinks C, Jeffery Aet al. Risk factors for onset of osteoarthritis of the knee in older adults: a systematic review and meta-analysis. Osteoarthritis Cartilage. 2010, 18: 24-33.
6. Bobyn J, Thompson R, Lim L, et al. Local alendronic acid elution increases net periimplant bone formation: a micro-CT analysis. Clin Orthop Relat Res.2014 Feb;472(2):687-94.
7. Brandt K, Mankin H, Shulman L. Workshop on etiopathogenesis of osteoarthritis, J Rheumatol 1986,13, 1126-1160.
8. Carbone L, Nevitt M, Wildy K, et al. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum 2004; 50(11): 3516–3525.Cecilian F, Giordano A, Spagnolo V. The systemic reaction during inflammation: the acute-phase proteins. Protein Pept Lett. 2002; 9: 211–223.
9. Clifton O, Chris J, Patrick G, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: Results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis and Rheumatism Volume 54, Issue 11November 2006 Pages 3494–3507.
10. Cryer B and Bauer D. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?Mayo Clin Proc. 2002 Oct;77(10):1031-43.
11. Dam E, Byrjalsen I, Karsdal M et al. Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. Osteoarthritis and Cartilage Volume 17, Issue 3, March 2009, Pages 384-389.
12. Esser S and Bailey A. Effects of exercise and physical activity on knee OA. Curr Pain Headache Rep.2011;15:423–30.
13. Evans K, Lau S, Oberbauer A, et al. Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta. Bone Volume 32, Issue 3, March 2003, Pages 268–274.
14. Evdo S. Hormone therapy in elderly women: a comparative study with alendronate of the effects on bone, cardiovascular risk factors, periodontal conditions and quality of life. Academic dissertation; Department of Obstetrics and Gynecology, and Division of Endocrinology, Department of Medicine, Helsinki University Central Hospital University of Helsinki, Finland. (2006) Pp 49.
15. Fernandes J, Martel-Pelletier J, Pelletier J. The role of cytokines in osteoarthritis pathophysiology. Biorheology. 2002;39(1-2):237-46.
16. Frank H, Anne-Marie L, Shuting S, et al. The relationship between the chemistry and biological activity of the bisphosphonates Bone Volume 49, Issue 1, July 2011, Pages 20–33.
17. Fujita T, Fujii Y, Oka SF, Miyachi Y, Takagi Y. Analgesic effect of etidronate on degenerative joint disease. J Bone Miner Metab 2001; 19: 251–256.
18. Galluzzo S, Santini D, Vincenzi B, et al. Immunomodulating role of bisphosphonates on human gamma delta T cells: an intriguing and promising aspect of their antitumour activity. Expert Opin Ther Targets 2007; 11: 941–954.
19. Gehua Z, Xu C. TGFβ signaling in subchondral bone and articular cartilage homeostasis. Trends in Pharmacological sciences Volume 35, Issue 5, May 2014, Pages 227–236.
20. Gehua Z, Chunyi W, XiaoFeng J, et al. Crane. Inhibition of TGF-β signaling in subchondral bone mesenchymal stem cells attenuates osteoarthritis. Nat Med. 2013 Jun; 19(6): 704–712.
21. He D, Yin M, Luo Y, Wei Q. Research progress of protective effects of alendronate on articular cartilage in osteoarthritis. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2012 Oct;26(10): 1187-90.
22. Heckbert S, Li G, Cummings S, Smith N, et al. Use of Alendronate and Risk of Incident Atrial Fibrillation in Women. Arch Intern Med. 2008; 168 (8): 826-831.
23. Horikawa A, Miyakoshi N., Shimada Y., et al. A comparative study between intravenous and oral alendronate administration for the treatment of osteoporosis. Springer Plus 2015; 4:675-679.
24. Hunter D. Advanced imaging in osteoarthritis. Bull NYU Hosp Jt Dis. 2008. 66(3): 251-60.
25. Hu H, Zhang L, Li B, et al. In vitro effect of alendronate on chondrocytes and articular cartilage and subchondral bone in rabbit anterior cruciate ligament transection model. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2009 Dec;23(12): 1474-81.İşeri O, Şener G, Yüksel M. Ghrelin against alendronate-induced gastric damage in rats J Endocrinol December 1 2005 187399-406.
26. Jia J, Yao W, Amugongo S, et al. Prolonged alendronate treatment prevents the decline in serum TGF-β1 levels and reduces cortical bone strength in long-term estrogen deficiency rat model. Bone 2013; 52: 424-432. Jinks C, Jordan K, Croft P. Measuring the population impact of knee pain and disability with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Pain 2002; 100: 55–64.
27. Jokar M, Mirfeizi Z, Keyvanpajoh K. The Effect of Alendronate on Symptoms of Knee Osteoarthritis: A Randomized Controlled Trial. Iranian Journal of Medical Sciences IJMS (2010) Vol 35, No 1:9-15. Jorge A, Santos C, Raquel L, et al. Osteoarthritis associated with estrogen deficiency. Arthritis Res Ther. 2009; 11(5): 241. Karsdal M, Bay-Jensen A, Lories R, et al. The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments? : Ann Rheum Dis 2014;73:336-348.
28. Keeffe F, Lefebvre J, Egert J, et al. The relationship of gender to pain, pain behavior, and disability in osteoarthritis patients: the role of catastrophizing. Pain. 2000 Sep;87(3):325-34.
29. Kellgren J, Lawrence J. Radiological assessment of osteoarthritis. Ann Rheum Dis. 1957;16:494–502.
30. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research American Society for Bone and Mineral Research J Bone Miner Res. 2007 Oct; 22(10):1479-91.
31. Kress B. Bone alkaline phosphatase: methods of quantitation and clinical utility. J Clin Ligand Assay. 1998; 21(2): 139–148.
32. Lenart A, Lorich G, Lane M. Atypical Fractures of the Femoral Diaphysis in Postmenopausal Women Taking Alendronate. N Engl J Med 2008; 358(12):1304-1306.
33. Lewis R. knee osteoarthritis: Acetaminophen least Effective Choice in Medscape. Jan 07, 2015.
34. Lin J. Bisphosphonates: A review of their pharmacokinetic properties.Bone Volume 18, Issue 2, February 1996, Pages 75-85.
35. Link T, Steinbach L, Ghosh S, et al. Osteoarthritis: MR imaging findings in different stages of disease and correlation with clinical findings. Radiology 2003; 226: 373–81.
36. Mahjoub M, Berenbaum F, Houard X. Why subchondral bone in osteoarthritis? The importance of the cartilage bone interface in osteoarthritis. Osteoporos Int. 2012 ;23(Suppl 8):841–846.
37. McConnell S, Kolopack P and Davis AM. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): a review of its utility and measurement properties. Arthritis Rheum 2001; 45:453–61.
38. Michael J, Julie C, Fraser P, et al. Biochemical and molecular mechanisms of action of bisphosphonates. Bone Volum 49, Issue 1, July 2011, Pages 34–41.
39. Miguel A, Salvador A, Tomas D, et al. Effects of Aminobisphosphonates and Thiazides in Patients With Osteopenia/Osteoporosis, Hypercalcemia, and Recurring Renal Calcium LithiasisUrology Volume 81, Issue 4, April 2013, Pages 731–737. Mohan G, Perilli E, Parkinson I, et al. Pre-emptive, early, and delayed alendronate treatment in a rat model of knee osteoarthritis: effect on subchondral trabecular bone microarchitecture and cartilage degradation of the tibia, bone/cartilage turnover, and joint discomfort. Osteoarthritis Cartilage. 2013 Oct;21(10):1595-604.
40. Naniwa T, Maeda T, Mizoshita T, et al. Alendronate-induced esophagitis: possible pathogenic role of hypersensitivity to alendronate. Intern Med. 2008;47(23):2083-5. Epub 2008 Dec 1.
41. Neogi M, Ensrud K, Bauer D, et al. The effect of alendronate on progression of spinal osteophytes and disc-space narrowing. Ann Rheum Dis 2008;67:1437-1440.
42. Nijs R, Jacobs J, Lems W, et al. Alendronate or Alfacalcidol in Glucocorticoid-Induced Osteoporosis N Engl J Med 2006; 355:675-684 August 17, 2006.
43. Nishii T, Tamura S, Shiomi T, et al. Alendronate treatment for hip osteoarthritis: prospective randomized 2-year trial. Clin Rheumatol (2013); 32(12): pp. 1759–1766.
44. Patricia A, Tina L, Jesse A, et al. Pain, Disability, and Depression in Osteoarthritis: Effects of Race and Sex Aging Health June 21, 2011.
45. Radin E and Rose R. Role of subchondral bone in the initiation and progression of cartilage damage. Clin Orthop 1986; 213: 34–40.
46. Reid I and Hosking D. Bisphosphonates in Paget's disease. Bone Volum 49, Issue 1, July 2011, Pages 89–94.
47. Richard E, Jennifer S, Nelson B, et al. Bisphosphonates for postmenopausal osteoporosis. Bone Volum 49, Issue 1, July 2011, Pages 82–88.
48. Rogers M. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003;9:2643-2658.
49. Rossini M, Adami S, Fracassi E, et al. Effects of intra-articular clodronate in the treatment of knee osteoarthritis: results of a double-blind, randomized placebo-controlled trial. Rheumatol Int, 35 (2015), pp. 255–263.
50. Saviola G and Santoro L. Clodronate in erosive osteoarthrosis of the hand: efficacy for pain and function recovery. G Ital Med Lav Ergon 2000; 22: 328–331.
51. Scanzello C and Goldring S. The role of synovitis in osteoarthritis pathogenesis. Bone. 2012 Aug; 51(2):249-57.
52. Sharma L. Osteoarthritis year in review 2015: clinical. OA and cartilage January 2016 Volume 24, Issue 1, Pages 36–48.
53. Siebelt M, Waarsing J, Groen H, et al. Inhibited osteoclastic bone resorption through alendronate treatment in rats reduces severe osteoarthritis progression. Bone. 2014 Sep; 66:163-70.
54. Spector T, Conaghan P, Buckland-Wright J, et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial. Arthritis Res Ther 2005; 7: R625-33.
55. Suri S and Walsh D. Osteochondral alterations in osteoarthritis. Bone. 2012;51(2):204–211.
56. Tadashi H, Maureen P, Gregg A, et al. The role of subchondral bone remodeling in osteoarthritis: Reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis & Rheumatology Volume 50, Issue 4 April 2004 Pages 1193–1206.
57. Van der Kraan P, Blaney Davidson E, van den Berg W. A role for age-related changes in TGFbeta signaling in aberrant chondrocyte differentiation and osteoarthritis. Arthritis Res Ther. 2010;12(1):201.
58. Van der P. Age-related alterations in TGFbeta signaling as a causal factor of cartilage degeneration in osteoarthritis. Biomed Mater Eng. 2014;24(1 Suppl):75-80.
59. Vijaykumar M, Gabriel B, Alison M, et al. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis and Rheumatology Volume 60, Issue 7 July 2009 Pages 2008–2018.
60. Voelker R. Few adults with knee osteoarthritis meet national guidelines for physical activity. JAMA.2011;306:1428–30.
61. Wang Z, Wang W, Zhang L, et al. Effect of alendronate on interleukin-1beta induced chondrocytes of rat in vitro. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2011 Jan;25(1):50-5.
62. Waikakul S, Sintuvanich N, Assanasuwan T, et al. Efficacy, Side Effects, Safety and Effects on Bone Turnover Markers of once a Week Sandoz Alendronate Sodium Trihydrate 70 mg. Malaysian Orthopaedic Journal 2011 Vol 5 No 2: 15-19.

63. Willem E, Bakker K, Floris P. Associations of CTX-II with biochemical markers of bone turnover raise questions on its tissue origin: data from CHECK, a cohort study of early osteoarthritis. Ann Rheum Dis 2013;72:29-36.

64. Yamada Y. Association of a Leu(10)→Pro polymorphism of the transforming growth factor-beta1 with genetic susceptibility to osteoporosis and spinal osteoarthritis. Mech Ageing Dev. 2000;116:113–123.

65. Yamada Y, Okuizumi H, Miyauchi A, et al. Association of transforming growth factor beta 1 genotype with spinal osteophytosis in Japanese women. Arthritis Rheum.2000;43:452–460.Zentiva. Alendronic Acid 70mg Tablets Last Updated on eMC 05-Feb-2016 View changes.Drug.comZhen G, Wen C, Jia X, et al. Inhibition of TGF-β signaling in subchondral bone mesenchymal stem cells attenuates osteoarthritis. Nature medicine. 2013;19(6):704-A.